Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation

2026-09-16
Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

2026-09-16
The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor

Should You Buy Donaldson Stock While Its Share Count Stops Shrinking?

2026-09-16
Donaldson (DCI) has gained 9.1% over the past twelve months and still trades about 20% below its 52-week high. The filtration company behind those numbers sells replacement parts into equipment already in service, and the cash from that stream has been steadily shrinking its share count. The shrinking count is the case for buying the pullback. It is also the part that goes quiet in fiscal 2027.

Danaher Announces Quarterly Dividend

2026-09-15
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.

ELV or DHR: Which Is the Better Value Stock Right Now?

2026-09-15
ELV vs. DHR: Which Stock Is the Better Value Option?

High Content Screening Market Forecasts Growth from $3.37B (2026) to $6.58B by 2032, Profiling Thermo Fisher, Danaher, GE HealthCare & 27 Other Key Players

2026-09-15
Opportunities center on AI-enabled imaging, lab automation, advanced 3D and patient-derived cell models, CRO partnerships, and expanding global life sciences research.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "High Content Screening Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global High Content Screening Market, projected to reach USD 3.37 billion in 2026 and USD 6.58 billion by 2032, representing a CAGR of 1

Single-Use Bioreactors Market by Product, Type, Cell Type, Molecule, Process Mode, Application, Competition, Region - Global Forecast to 2031

2026-09-15
The global single-use bioreactors market is forecast to grow from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, at a 12.0% CAGR. Growth is driven by biologics, biosimilars, vaccine manufacturing, CDMO outsourcing, and flexible bioprocessing. Bioproduction and monoclonal antibodies led the market in 2025, while Asia Pacific is expected to grow fastest through 2031. Key players include Sartorius, Danaher, Thermo Fisher Scientific, and Merck KGaA.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "

Tracking Dan Loeb's Third Point Portfolio - Q2 2026 Update

2026-09-10
Third Point’s Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.

3 Reasons DHR is Risky and 1 Stock to Buy Instead

2026-09-10
Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.

Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says

2026-09-09
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re